Tenderwize
Zurück zur Suche

Open-house rebate agreements for Etanercept

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 05, 2026 · 8 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Etanercept, ATC L04AB01

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

52 / 100

Komplexität

58 / 100

Risikofaktoren

For paper submissions, the notice requires duplicate originals and a prior fax/scan/email/portal transmission only pres...

Participation is limited to pharmaceutical companies and requires a signed reliability self-declaration.

Submission deadline in 8 days

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Non-exclusive rebate agreements for the medicinal product Etanercept, ATC L04AB01.
  • Open-house model with identical, pre-set contract terms for all eligible pharmaceutical companies.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for pharmaceutical products: non-exclusive rebate agreements for Etanercept (ATC L04AB01) offered by AOK Bayern to all interested pharmaceutical companies that meet the stated suitability requirement. This is explicitly described as a non-competitive open-house model with no selection decision and no negotiated terms. Contracting is possible throughout the term, with the latest contract conclusion date on 2026-09-05. Submission can be made electronically with a qualified electronic signature or in paper form; documents not in German must be submitted with a German translation.

Risiken

For paper submissions, the notice requires duplicate originals and a prior fax/scan/email/portal transmission only pres...

Participation is limited to pharmaceutical companies and requires a signed reliability self-declaration.

Submission deadline in 8 days

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submission of a completed and signed self-declaration on reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submission of the completed and signed contract and the completed and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreements for Etanercept

Open-house supply lot for non-exclusive rebate agreements concerning the active substance Etanercept (ATC L04AB01). The notice states that all interested pharmaceutical companies meeting the suitability requirement may join on identical, non-individually negotiable terms. Place of performance is Germany, specifically DE212 (Bavaria/Munich region in the notice metadata).

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Oct 2024 - Oct 2026

Kategorie

Pharmaceutical products

Frist

Deadline Sep 05, 2026

Vergabedetails

Veröffentlichungsdatum
16 Sep 2024
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
557440-2024

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30